Regenxbio (RGNX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $6.93, -3.28% vs the prior close of $7.16.
- Volume 1.21M shares, 0.9x its 50-day average.
- New SEC filings: 8-K (Oct 16, 2026).
- No new insider buys or sales reported since the prior session.
RGNX slides 3.3% to $6.93. Closed at $6.93, -3.28% vs the prior close of $7.16. Day range $6.88–$7.18, opened at $7.15.
RGNX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — RGNX slides 3.3% to $6.93
- Closed at $6.93, -3.28% vs the prior close of $7.16. Day range $6.88–$7.18, opened at $7.15.
- Volume was 1.21M shares, 0.9x its 50-day average of 1.40M.
- Price is -21.0% vs its 50-day average ($8.76) and -27.4% vs its 200-day average ($9.54).
- 52-week range $5.45–$16.19; today's close sits at 14% of that range, 57.2% below the 52-week high.
Oct 15, 2026 — RGNX jumps 4.1% to $7.16
- Closed at $7.16, +4.07% vs the prior close of $6.88. Day range $6.83–$7.28, opened at $6.88.
- Volume was 1.23M shares, 0.9x its 50-day average of 1.40M.
- Price is -19.1% vs its 50-day average ($8.85) and -25.3% vs its 200-day average ($9.58).
- 52-week range $5.45–$16.19; today's close sits at 16% of that range, 55.8% below the 52-week high.
Oct 14, 2026 — RGNX slides 5.2% to $6.88, a 3-month low, 4 down days in a row
- Closed at $6.88, -5.23% vs the prior close of $7.26. Day range $6.80–$7.24, opened at $7.12.
- Volume was 1.56M shares, 1.1x its 50-day average of 1.39M.
- Price is -22.8% vs its 50-day average ($8.92) and -28.5% vs its 200-day average ($9.62).
- 52-week range $5.45–$16.19; today's close sits at 13% of that range, 57.5% below the 52-week high.
- That makes 4 straight losses.
Oct 13, 2026 — RGNX slides 6.6% to $7.26, 3 down days in a row
- Closed at $7.26, -6.56% vs the prior close of $7.77. Day range $7.11–$7.72, opened at $7.66.
- Volume was 1.38M shares, 1.0x its 50-day average of 1.38M.
- Price is -19.2% vs its 50-day average ($8.98) and -24.8% vs its 200-day average ($9.65).
- 52-week range $5.45–$16.19; today's close sits at 17% of that range, 55.2% below the 52-week high.
- That makes 3 straight losses.
Oct 12, 2026 — RGNX slides 3.7% to $7.77
- Closed at $7.77, -3.72% vs the prior close of $8.07. Day range $7.74–$8.29, opened at $8.12.
- Volume was 2.03M shares, 1.5x its 50-day average of 1.36M.
- Price is -14.0% vs its 50-day average ($9.04) and -19.8% vs its 200-day average ($9.69).
- 52-week range $5.45–$16.19; today's close sits at 22% of that range, 52.0% below the 52-week high.
Oct 9, 2026 — RGNX ends flat (-0.2%) to $8.07
- Closed at $8.07, -0.25% vs the prior close of $8.09. Day range $7.95–$8.27, opened at $8.03.
- Volume was 859.10K shares, 0.6x its 50-day average of 1.37M.
- Price is -11.1% vs its 50-day average ($9.08) and -17.0% vs its 200-day average ($9.72).
- 52-week range $5.45–$16.19; today's close sits at 24% of that range, 50.2% below the 52-week high.
Oct 8, 2026 — RGNX jumps 6.5% to $8.09
- Closed at $8.09, +6.52% vs the prior close of $7.59. Day range $7.44–$8.31, opened at $7.50.
- Volume was 2.26M shares, 1.7x its 50-day average of 1.34M.
- Price is -11.3% vs its 50-day average ($9.12) and -17.1% vs its 200-day average ($9.76).
- 52-week range $5.45–$16.19; today's close sits at 25% of that range, 50.0% below the 52-week high.
Oct 7, 2026 — RGNX rises 1.9% to $7.59
- Closed at $7.59, +1.95% vs the prior close of $7.45. Day range $7.20–$7.73, opened at $7.31.
- Volume was 1.00M shares, 0.7x its 50-day average of 1.35M.
- Price is -17.0% vs its 50-day average ($9.15) and -22.4% vs its 200-day average ($9.79).
- 52-week range $5.45–$16.19; today's close sits at 20% of that range, 53.1% below the 52-week high.
Oct 6, 2026 — RGNX slides 4.0% to $7.45
- Closed at $7.45, -3.99% vs the prior close of $7.76. Day range $7.33–$7.84, opened at $7.79.
- Volume was 1.16M shares, 0.9x its 50-day average of 1.35M.
- Price is -18.9% vs its 50-day average ($9.19) and -24.1% vs its 200-day average ($9.82).
- 52-week range $5.45–$16.19; today's close sits at 19% of that range, 54.0% below the 52-week high.
Oct 5, 2026 — RGNX jumps 4.4% to $7.76
- Closed at $7.76, +4.44% vs the prior close of $7.43. Day range $7.57–$8.16, opened at $7.80.
- Volume was 2.35M shares, 1.8x its 50-day average of 1.33M.
- Price is -16.0% vs its 50-day average ($9.23) and -21.2% vs its 200-day average ($9.85).
- 52-week range $5.45–$16.19; today's close sits at 21% of that range, 52.1% below the 52-week high.
Oct 2, 2026 — RGNX ends flat (+0.1%) to $7.43
- Closed at $7.43, +0.13% vs the prior close of $7.42. Day range $7.36–$7.62, opened at $7.58.
- Volume was 1.04M shares, 0.8x its 50-day average of 1.33M.
- Price is -19.9% vs its 50-day average ($9.27) and -24.8% vs its 200-day average ($9.88).
- 52-week range $5.45–$16.19; today's close sits at 18% of that range, 54.1% below the 52-week high.
RGNX latest news & SEC filings
Every SEC filing by or about RGNX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 16, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Oct 13, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
Sep 3, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 3, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 27, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Ciongoli Gregory Austin bought 53,407 shares at $9.36 (≈$499.89K) on Aug 27, 2026
- Ciongoli Gregory Austin bought 53,407 shares at $9.36 (≈$499.89K) on Aug 27, 2026
- Ciongoli Gregory Austin bought 53,407 shares at $9.36 (≈$499.89K) on Aug 27, 2026
- Ciongoli Gregory Austin bought 53,407 shares at $9.36 (≈$499.89K) on Aug 27, 2026
- Ciongoli Gregory Austin bought 49,196 shares at $9.14 (≈$449.65K) on Aug 26, 2026
- Ciongoli Gregory Austin bought 49,196 shares at $9.14 (≈$449.65K) on Aug 26, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 27, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Aug 25, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 24, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $108.02M (prior year $21.36M) (+405.7% vs Jun 30, 2025)
- Net income: $22.71M (prior year -$70.87M) (swung to profit vs Jun 30, 2025)
- Diluted EPS: $0.43 (prior year -$1.38) (swung to profit vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 4, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 4, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 20, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Jul 17, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Things to know before you trade RGNX
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 14, 2026, Mar 5, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.14% (largest 8.0%). That is a volatile stock.
- Liquidity: about 1.46M shares (≈$10.12M) trade per day on average.
- 52-week position: $6.93 vs a range of $5.45–$16.19 (14% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 8 open-market buys, 17 sales; latest: Gregory Austin Ciongoli bought 53,407 shares on Aug 27, 2026.
- Latest filings: 8-K Oct 16, 2026; 8-K Sep 23, 2026; 8-K Aug 25, 2026.
- Share count: 66.01M shares outstanding (Jul 31, 2026), +30.7% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
RGNX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 7.15 | 7.18 | 6.88 | 6.93 | 1.21M |
| Oct 15, 2026 | 6.88 | 7.28 | 6.83 | 7.16 | 1.23M |
| Oct 14, 2026 | 7.12 | 7.24 | 6.80 | 6.88 | 1.56M |
| Oct 13, 2026 | 7.66 | 7.72 | 7.11 | 7.26 | 1.38M |
| Oct 12, 2026 | 8.12 | 8.29 | 7.74 | 7.77 | 2.03M |
| Oct 9, 2026 | 8.03 | 8.27 | 7.95 | 8.07 | 859.10K |
| Oct 8, 2026 | 7.50 | 8.31 | 7.44 | 8.09 | 2.26M |
| Oct 7, 2026 | 7.31 | 7.73 | 7.20 | 7.59 | 1.00M |
| Oct 6, 2026 | 7.79 | 7.84 | 7.33 | 7.45 | 1.16M |
| Oct 5, 2026 | 7.80 | 8.16 | 7.57 | 7.76 | 2.35M |
| Oct 2, 2026 | 7.58 | 7.62 | 7.36 | 7.43 | 1.04M |
| Oct 1, 2026 | 7.52 | 7.74 | 7.30 | 7.42 | 1.71M |
| Sep 30, 2026 | 7.49 | 7.86 | 7.35 | 7.53 | 1.79M |
| Sep 29, 2026 | 7.41 | 7.64 | 7.33 | 7.45 | 2.10M |
| Sep 28, 2026 | 7.30 | 7.49 | 7.17 | 7.47 | 1.33M |
| Sep 25, 2026 | 7.53 | 7.68 | 7.16 | 7.40 | 1.28M |
| Sep 24, 2026 | 7.45 | 7.46 | 7.12 | 7.24 | 1.51M |
| Sep 23, 2026 | 8.13 | 8.15 | 7.40 | 7.50 | 1.11M |
| Sep 22, 2026 | 8.03 | 8.25 | 7.90 | 8.15 | 1.20M |
| Sep 21, 2026 | 8.24 | 8.31 | 7.76 | 7.88 | 1.12M |
About Regenxbio
Regenxbio (RGNX) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in ROCKVILLE, MD. Fiscal year ends December 31. SEC CIK 1590877.
RGNX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Jean Bennett | Director | Jun 2, 2026 |
| Gregory Austin Ciongoli | Director | Aug 27, 2026 |
| Allan M. Fox | Director | Jun 2, 2026 |
| Alexandra Glucksmann | Director | Jun 2, 2026 |
| Argeris N Karabelas | Director | Jun 2, 2026 |
| George V Migausky | Director | Jun 2, 2026 |
| Kenneth T. Mills | Director | Jun 2, 2026 |
| David C Stump | Director | Jun 2, 2026 |
| Curran Simpson | Chief Executive Officer | Jul 6, 2026 |
| Daniel Tasse | Director | Jun 2, 2026 |
| Jennifer Zachary | Director | Jun 2, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Mitchell Chan | Chief Financial Officer | Sep 3, 2026 |
| Patrick J. Christmas | Chief Strategy & Legal Officer | Aug 4, 2026 |
| Craig Malzahn | Chief Technology Officer | Sep 3, 2026 |
| Steve Pakola | Chief Medical Officer | Aug 4, 2026 |
| Curran Simpson | Chief Executive Officer | Jul 6, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 27, 2026 | Gregory Austin Ciongoli | Buy | 53,407 | $9.36 |
| Aug 27, 2026 | Gregory Austin Ciongoli | Buy | 53,407 | $9.36 |
| Aug 27, 2026 | Gregory Austin Ciongoli | Buy | 53,407 | $9.36 |
| Aug 27, 2026 | Gregory Austin Ciongoli | Buy | 53,407 | $9.36 |
| Aug 26, 2026 | Gregory Austin Ciongoli | Buy | 49,196 | $9.14 |
| Aug 26, 2026 | Gregory Austin Ciongoli | Buy | 49,196 | $9.14 |
| Aug 26, 2026 | Gregory Austin Ciongoli | Buy | 49,196 | $9.14 |
| Aug 26, 2026 | Gregory Austin Ciongoli | Buy | 49,196 | $9.14 |
| Jul 2, 2026 | Steve Pakola | Sale | 2,161 | $13.64 |
| Jul 2, 2026 | Steve Pakola | Sale | 2,161 | $13.64 |
| Jul 2, 2026 | Steve Pakola | Sale | 2,161 | $13.64 |
| Jul 2, 2026 | Steve Pakola | Sale | 2,161 | $13.64 |
| Jul 1, 2026 | Steve Pakola | Sale | 36,725 | $12.86 |
| Jul 1, 2026 | Steve Pakola | Sale | 36,725 | $12.86 |
| Jul 1, 2026 | Steve Pakola | Sale | 36,725 | $12.86 |
RGNX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $170.44M | $-193.88M | -3.76 | $-123.96M |
| Dec 31, 2024 | $83.33M | $-227.10M | -4.59 | $-173.12M |
| Dec 31, 2023 | $90.24M | $-263.49M | -6.02 | $-218.41M |
| Dec 31, 2022 | $112.72M | $-280.32M | -6.50 | $-207.49M |
| Dec 31, 2021 | $470.35M | $127.84M | 2.91 | $218.88M |
Latest balance sheet: total assets $386.62M, total liabilities $314.85M, cash $36.49M (as of Jun 30, 2026).
RGNX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $11.28 |
| May 14, 2026 | 8-K Item 2.02 (results) | $6.24 |
| Mar 5, 2026 | 8-K Item 2.02 (results) | $8.72 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $11.17 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $7.90 |
| May 12, 2025 | 8-K Item 2.02 (results) | $7.97 |
| Mar 13, 2025 | 8-K Item 2.02 (results) | $6.55 |
| Nov 6, 2024 | 8-K Item 2.02 (results) | $9.43 |
| Aug 1, 2024 | 8-K Item 2.02 (results) | — |
| May 8, 2024 | 8-K Item 2.02 (results) | — |
| Feb 27, 2024 | 8-K Item 2.02 (results) | — |
| Nov 8, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on RGNX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.